News

The Emmes Corporation today announced that Dr. Paul VanVeldhuisen, chief operating officer and principal investigator, co-authored a study published by the Journal of the American Medical Association (JAMA). The study focused on the efficacy and safety of a commonly used, off-label drug called Avastin in treating macular edema due to central retinal vein occlusion. The study also addressed how Avastin compared to another drug, Eylea, which has been approved by the FDA and is being used to treat the same disease. The 2-1/2-year study with nearly 400 patients concluded that Avastin was as effective as Eylea in improving vision after six months of treatment. The cost of Avastin is $60 per dose compared to Eylea’s $1,850 per dose.

The Emmes Corporation today announced a contract spanning just over four years for a Phase 2 study of a Zika vaccine. The contract, valued at up to $27.6 million, expands the initial Phase 1 testing that began last year. This is the first-ever Phase 2 study for a Zika vaccine. Dr. Anne Lindblad, president and chief executive officer of Emmes, said, “The win is important because it expands our role in combating the Zika virus, a significant and enduring public health challenge.”

The Emmes Corporation today announced the highest revenues in its 40‐year history along with significant growth in its employee count. Revenues surpassed $90 million in 2016, and it employed 567 employees in its U.S. and international offices.

The Emmes Corporation today announced that a large team of scientists and health professionals including those from the company, LDS Hospital in Salt Lake City, Utah, Lovelace Biomedical Environmental Research Institute in Albuquerque, New Mexico, and the U.S. Army Medical and Materiel Development Activity at Fort Detrick, Maryland, have authored a series of papers summarizing significant research on traumatic brain injury in the military.

The Emmes Corporation today announced that it contributed to a landmark research study by the National Institutes of Health linking air pollution and preterm birth risk in pregnant women with asthma. The study, published in the Journal of Allergy and Clinical Immunology, reported that pregnant women with asthma have an increased risk for preterm birth when exposed to high levels of nitrogen oxides and carbon monoxide, common traffic-related air pollutants.

The Emmes Corporation today announced that Dr. Paul VanVeldhuisen has been promoted to the newly created position of chief operating officer. Dr. VanVeldhuisen, who started at Emmes as a statistician and epidemiologist, will assume the additional leadership responsibilities while continuing to serve as principal investigator for government and privately funded research projects.

The Emmes Corporation today announced that three of its statisticians, Dr. Ravinder Anand, Dr. Traci Clemons and Karen Martz, co-authored a pivotal study that examined lithium as a treatment for pediatric bipolar I disorder. The study was published in the October issue of Pediatrics.

The Emmes Corporation today announced that one of its principal investigators and statisticians, Dr. Traci Clemons, co-authored a study that was just published by the Journal of the American Medical Association (JAMA).

The New "Mercy TAPE" Estimates Pediatric Weight with Greater Accuracy, Giving Doctors a Better Tool for Determining Prescription Dosage.

EMMES to Coordinate NCI Anal Cancer Prevention Study

The EMMES Corporation today announced that it has been awarded an indefinite delivery, indefinite quantity (IDIQ) contract to become part of a clinical studies network established by the Biomedical Advanced Research and Development Authority (BARDA) to perform studies needed to develop medical countermeasures against agents of bioterrorism, pandemic influenza, and other public health threats.

When she was young, Anne Lindblad was interested in medicine, even becoming a physician, until she came face-to-face with the inevitable frog to dissect in high school biology class.